Lantern Pharma Inc. Common Stock (LTRN) is a publicly traded Healthcare sector company. As of May 21, 2026, LTRN trades at $3.17 with a market cap of $38.28M and a P/E ratio of -2.01. LTRN moved +2.91% today. Year to date, LTRN is -2.46%; over the trailing twelve months it is -8.91%. Its 52-week range spans $1.11 to $6.12. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces LTRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lantern Pharma Cuts Costs 19%, Posts $17.1M Net Loss and Secures FDA IND: Lantern Pharma cut operating expenses by 19% year-over-year yet recorded a $17.1 million net loss for 2025 and warned of substantial funding needs. It secured FDA IND clearance for its pediatric CNS cancer program, dosed over 100 patients, and saw an 86% clinical benefit rate in its LP-300 trial.
| Metric | Value |
|---|---|
| Price | $3.17 |
| Market Cap | $38.28M |
| P/E Ratio | -2.01 |
| EPS | $-1.57 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.12 |
| 52-Week Low | $1.11 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-17.12M |
| Gross Margin | 0.00% |
1 analysts cover LTRN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.